TOPAS COC Polymer Used in Insulin Pump Upgrade
Pharmapack North America exhibitor TOPAS Advanced Polymers has provided TOPAS cyclic olefin copolymer (COC) for a recently upgraded insulin pump. The next-generation OmniPod Insulin Management System upgraded by developer Insulet Corp. features an insert molded plunger made from TOPAS COC. The tubeless and wireless insulin pump offers people living with insulin-requiring diabetes a portable solution.
Pharmapack North America takes place this week (June 18-19) in Philadelphia.
The newly released OmniPod is 34% smaller and 25% lighter than the original model, and it received 510(k) clearance from the U.S. FDA in December 2012, TOPAS reported in a press release. TOPAS COC, which provides purity, drug compatibility, biocompatibility, and dimensional stability, has been used in this critical high-performance plunger since the first-generation device was commercialized in late 2005, the company reports.
The OmniPod Insulin Management System consists of the OmniPod, which holds and delivers the insulin. The OmniPod features a two-component insert-molded plunger that consists of a stainless steel lead-screw and fill rod, which are insert-molded with TOPAS COC resin. The two-component plunger has an elliptical shape and measures approximately 3/8-in (9.5 mm) by 5/8-in (15.9 mm).
The dimensions of the plunger and lead-screw are critical because small amounts of insulin have a significant effect on blood sugar levels, the company reports. TOPAS COC provides strong dimensional stability since the plunger moves just 0.000156-in (0.004 mm) per increment of insulin delivery, it reports.
The OmniPod attaches directly to the body and is usable for up to three days of basal-bolus insulin therapy – delivering boluses of insulin after meals and in steady rates throughout the day. The OmniPod holds 200 units of rapid-acting insulin, which Insulet says meets the needs of most Type 1 diabetes patients’ three-day insulin requirements.
The material’s stability helps successfully manage the plunger and reservoir interface, which is critical to the function of the device and provides adequate compression to maintain seal integrity, explained Kevin Schmid, Insulet’s Vice President of Business Development and Advanced Technology, in the press release.
“TOPAS COC fills an important role in the drive system of the OmniPod Insulin Management System,” said Schmid. “It’s a well-respected material because of its drug compatibility and other high-performance attributes.”
TOPAS COC offers a non-ionic, minimally reactive surface, reports TOPAS. This non-polar substrate does not promote adsorption, denaturation, aggregation, or precipitation. With lower leachables and extractables, glass-clear TOPAS resin preserves long-term drug purity enabling better quality at high yields.
To read more about how people with diabetes are using OmniPod, visit the customer blog, Suite D: http://suited.myomnipod.com. Founded in 2000, Insulet Corporation is based in Bedford, Mass. For more information, visit: http://www.myomnipod.com.
TOPAS Advanced Polymers will be exhibiting in Booth #313 at Pharmapack North America. For more information about the company, visit www.topas.com.